China Resources Double-Crane Pharmaceutical Co Ltd Cash Flow Conversion Efficiency

Latest as of September 2025: 0.040x

China Resources Double-Crane Pharmaceutical Co Ltd cash flow conversion efficiency. Based on the latest financial reports, China Resources Double-Crane Pharmaceutical Co Ltd (600062) has a cash flow conversion efficiency ratio of 0.040x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥487.90 Million ≈ $71.40 Million USD) by net assets (CN¥12.16 Billion ≈ $1.78 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see China Resources Double-Crane Pharmaceuti (600062) total market value for the company's overall valuation and market capitalisation.

Cash Flow Conversion Efficiency of China Resources Double-Crane Pharmaceutical Co Ltd (1998–2024)

Cash flow conversion efficiency of China Resources Double-Crane Pharmaceutical Co Ltd from 1998 to 2024. This chart illustrates how China Resources Double-Crane Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View China Resources Double-Crane Pharmaceuti share price for real-time trading data and today's change.

China Resources Double-Crane Pharmaceutical Co Ltd Cash Flow Conversion Ratio Explained

China Resources Double-Crane Pharmaceutical Co Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

China Resources Double-Crane Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of China Resources Double-Crane Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency. Review how much free cash does China Resources Double-Crane Pharmaceuti generate to assess how much free cash flow the company generates relative to operating cash flow.

Company	Cash Flow Conversion Efficiency
Shenzhen Kstar Science & Technology Co Ltd SHE:002518	0.074x
P/F Bakkafrost F:6BF	0.040x
Eutelsat Communications SA PA:ETL	0.071x
Urban Edge Properties NYSE:UE	0.028x
Macrolink Real Estate Co Ltd SHE:000620	0.010x
Grindr Inc NYSE:GRND	-3.476x
Four Corners Property Trust Inc NYSE:FCPT	0.031x
Ebos Group Ltd AU:EBO	0.017x

Annual Cash Flow Conversion Efficiency for China Resources Double-Crane Pharmaceutical Co Ltd (1998–2024)

The table below shows the annual cash flow conversion efficiency of China Resources Double-Crane Pharmaceutical Co Ltd from 1998 to 2024. Also see 600062 asset base for a full breakdown of the balance sheet.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	CN¥11.11 Billion ≈ $1.63 Billion	CN¥1.83 Billion ≈ $267.07 Million	0.164x	+17.31%
2023-12-31	CN¥11.79 Billion ≈ $1.73 Billion	CN¥1.65 Billion ≈ $241.56 Million	0.140x	+11.98%
2022-12-31	CN¥10.73 Billion ≈ $1.57 Billion	CN¥1.34 Billion ≈ $196.33 Million	0.125x	-2.30%
2021-12-31	CN¥10.48 Billion ≈ $1.53 Billion	CN¥1.34 Billion ≈ $196.22 Million	0.128x	-11.76%
2020-12-31	CN¥9.38 Billion ≈ $1.37 Billion	CN¥1.36 Billion ≈ $199.03 Million	0.145x	-12.59%
2019-12-31	CN¥8.68 Billion ≈ $1.27 Billion	CN¥1.44 Billion ≈ $210.69 Million	0.166x	-10.67%
2018-12-31	CN¥7.91 Billion ≈ $1.16 Billion	CN¥1.47 Billion ≈ $214.97 Million	0.186x	+22.81%
2017-12-31	CN¥7.85 Billion ≈ $1.15 Billion	CN¥1.19 Billion ≈ $173.71 Million	0.151x	+38.03%
2016-12-31	CN¥7.04 Billion ≈ $1.03 Billion	CN¥771.25 Million ≈ $112.86 Million	0.110x	+0.52%
2015-12-31	CN¥6.43 Billion ≈ $941.48 Million	CN¥701.35 Million ≈ $102.63 Million	0.109x	-13.74%
2014-12-31	CN¥5.68 Billion ≈ $831.80 Million	CN¥718.38 Million ≈ $105.12 Million	0.126x	+23.46%
2013-12-31	CN¥5.34 Billion ≈ $780.86 Million	CN¥546.24 Million ≈ $79.93 Million	0.102x	+21.65%
2012-12-31	CN¥4.71 Billion ≈ $688.74 Million	CN¥396.05 Million ≈ $57.95 Million	0.084x	-28.55%
2011-12-31	CN¥4.34 Billion ≈ $635.56 Million	CN¥511.53 Million ≈ $74.85 Million	0.118x	-9.28%
2010-12-31	CN¥3.93 Billion ≈ $574.49 Million	CN¥509.67 Million ≈ $74.58 Million	0.130x	+34.17%
2009-12-31	CN¥3.53 Billion ≈ $517.25 Million	CN¥342.01 Million ≈ $50.05 Million	0.097x	-8.10%
2008-12-31	CN¥3.15 Billion ≈ $461.01 Million	CN¥331.71 Million ≈ $48.54 Million	0.105x	+5.74%
2007-12-31	CN¥2.36 Billion ≈ $346.03 Million	CN¥235.46 Million ≈ $34.45 Million	0.100x	-34.59%
2006-12-31	CN¥2.00 Billion ≈ $291.96 Million	CN¥303.71 Million ≈ $44.44 Million	0.152x	+111.19%
2005-12-31	CN¥1.94 Billion ≈ $283.78 Million	CN¥139.78 Million ≈ $20.45 Million	0.072x	-72.56%
2004-12-31	CN¥1.73 Billion ≈ $252.76 Million	CN¥453.72 Million ≈ $66.39 Million	0.263x	+202.75%
2003-12-31	CN¥1.72 Billion ≈ $251.20 Million	CN¥148.94 Million ≈ $21.79 Million	0.087x	-0.99%
2002-12-31	CN¥1.60 Billion ≈ $234.85 Million	CN¥140.63 Million ≈ $20.58 Million	0.088x	-7.41%
2001-12-31	CN¥1.49 Billion ≈ $218.03 Million	CN¥141.01 Million ≈ $20.63 Million	0.095x	-53.16%
2000-12-31	CN¥855.27 Million ≈ $125.15 Million	CN¥172.81 Million ≈ $25.29 Million	0.202x	+9.25%
1999-12-31	CN¥711.23 Million ≈ $104.08 Million	CN¥131.54 Million ≈ $19.25 Million	0.185x	+826.55%
1998-12-31	CN¥541.45 Million ≈ $79.23 Million	CN¥-13.78 Million ≈ $-2.02 Million	-0.025x	--

About China Resources Double-Crane Pharmaceutical Co Ltd

SHG:600062 China Drug Manufacturers - Specialty & Generic

Market Cap

$2.43 Billion

CN¥16.62 Billion CNY

Market Cap Rank

#5398 Global

#933 in China

Share Price

CN¥16.00

Change (1 day)

+0.44%

52-Week Range

CN¥15.60 - CN¥19.70

All Time High

CN¥33.06